Medtronic Stock Rises on Better-Than-Expected Q1 Results

Key Highlights

• Revenue grew 4.5% to $8.77 billion.
• Organic growth was 6.0%.
• GAAP diluted EPS decreased 16% to $0.59.

Financial Performance Details

Medtronic's revenue for the first quarter of fiscal year 2025 (Q1 FY25) was $8.77 billion, an increase of 4.5% as reported and 6.0% organically compared to the same period in the previous year.

Organic growth, which excludes the impact of acquisitions, divestitures, and currency fluctuations, was driven by strong demand for Medtronic's products in all operating segments.

GAAP diluted EPS for Q1 FY25 was $0.59, a decrease of 16% compared to $0.71 in the prior-year quarter.

Future Earnings Dates

• FY25 Q2: November 19, 2024
• FY25 Q3: February 18, 2025
• FY25 Q4: May 21, 2025

Analyst Commentary

Analysts view Medtronic's Q1 FY25 results as slightly better than expected, with revenue growth exceeding consensus estimates and organic growth remaining strong.

However, concerns remain about the impact of macroeconomic headwinds, including inflation and supply chain disruptions, on Medtronic's future performance.

Company Outlook

Medtronic CEO Geoff Martha expressed confidence in the company's long-term growth prospects and reaffirmed its commitment to innovation and customer focus.

The company remains optimistic about the demand for its products, particularly in emerging markets and in areas such as cardiovascular health, diabetes, and spine surgery.